Influenza vaccine safety data - 60 years and older (adjuvanted or high dose vaccine)

Data on this page show the responses of individuals aged 60 years and older who received an adjuvanted or high dose influenza vaccine and completed an AusVaxSafety survey sent in the days following vaccination.  The vaccines currently in use in this age group include Fluad® Quad and Fluzone® High-Dose Quadrivalent. These data provide you with a profile of what to expect in the days following your influenza vaccination and can assist when planning for your influenza vaccination.

AusVaxSafety surveillance of 2023 seasonal flu vaccines has concluded with no safety issues identified. Recommencement of surveillance will coincide with the release of 2024 seasonal influenza vaccines.

AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities.

Links to further information on the influenza vaccines are available below:

• Australian Government Department of Health and Aged Care influenza vaccine information for consumers
• Australian Technical Advisory Group on Immunisation (ATAGI) advice on seasonal influenza vaccines in 2023
• National Centre for Immunisation Research and Surveillance influenza vaccine resources for health professionals and the public